Proposed guidelines for the clinical evaluation of interleukin-1 inhibitors in the treatment of rheumatoid arthritis.
Since the effects of interleukin-1 might contribute to the lesions observed in rheumatoid arthritis. a compound which inhibits this cytokine should be an important addition to the therapeutic agents available for use in this disease. Clinical evaluation of such a compound must answer the following questions: Is the proposed drug "quick" or "slow" acting on the clinical and/or biological symptoms of inflammation? Is the proposed drug able to prevent and/or to stop the cartilage damage in rheumatoid arthritis? We propose some methodological guidelines for clinical trials designed to assess these compounds.
Dougados
M
M
René Descartes University, Department of Rheumatology, Hôpital Cochin, Paris, France.
D000700:Analgesics / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D002356:Cartilage / Q000187:drug effects / Q000473:pathology; D002986:Clinical Trials as Topic / Q000379:methods; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1 / Q000037:antagonists & inhibitors* / Q000502:physiology; D011506:Proteins / Q000494:pharmacology / Q000627:therapeutic use; D011971:Receptors, Immunologic / Q000187:drug effects; D017472:Receptors, Interleukin-1; D012107:Research Design; D012795:Sialoglycoproteins
D000700:Analgesics; D000893:Anti-Inflammatory Agents; C507763:IL1RN protein, human; D007155:Immunologic Factors; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1; D011506:Proteins; D011971:Receptors, Immunologic; D017472:Receptors, Interleukin-1; D012795:Sialoglycoproteins